Blood test may predict brain tumor return

NCT ID NCT07282470

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at epigenetic changes in meningioma tumors and blood samples to find markers that could predict if the tumor will come back after surgery. Researchers will analyze tissue from past patients and collect blood from new patients. The goal is to improve personalized care for people with this common brain tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a blood test that helps doctors predict which meningiomas are likely to come back after surgery.

What could go wrong

This is an observational study, not a treatment trial. The findings may not lead to immediate changes in patient care, and the epigenetic markers may not prove reliable in larger, diverse groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracranial meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••